Hormonal therapy for climacteric syndrome under the new coronavirus infection COVID-19
https://doi.org/10.51922/1818-426X.2022.4.144
Abstract
A modern obstetrician-gynecologist often faces the problem of correcting the negative changes that occur in the female body in the perimenopausal period. According to the WHO, by 2025 the number of women over the age of 60 will reach 1 billion, which undoubtedly makes the topic of menopausal syndrome therapy discussed by the authors of the article relevant. Since 2020, the global community has been living in a pandemic caused by the novel coronavirus SARS-CoV-2. And this undoubtedly affects the tactics of treating patients with other pathologies when this infection is attached. A certain alertness is caused by the influence of menopausal hormonal therapy on the hemostasis system. The new coronavirus infection (COVID-19) also activates a wide range of pathological links, affecting many body systems, including the hemostasis system. The authors reviewed a modern approach to the correction of menopausal changes in women using menopausal hormone therapy, the main indications and contraindications for its appointment, including in the context of the COVID-19 pandemic, based on the recommendations of international communities on menopause.
About the Authors
L. N. Vasil'eva
Белорусский государственный медицинский университет
Belarus
Belarus
E. V. Nikitina
Белорусский государственный медицинский университет
Belarus
Belarus
O. S. Lobachevskaya
Белорусский государственный медицинский университет
Belarus
Belarus
N. N. Rubahova
Белорусская медицинская академия последипломного образования
Belarus
Belarus
References
1. Zhenshchiny i muzhchiny Respubliki Belarus’. 2018: Statisticheskij sbornik / red. koll.: I. V. Medvedeva, I. S. Kangro, Zh. N. Vasilevskaya [et al.]. – M.: Belstat, 2018.
2. Klinicheskie rekomendacii. Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. Rossijskoe obshchestvo akusherov-ginekologov. Minzdrav Rossii. – M., 2021.
3. Kuznecov, M. R., Reshetov I. V., Papysheva O. V. et al. Menopauzal’naya gormonal’naya terapiya v usloviyah pandemii COVID-19 // Lechebnoe delo. – 2020. – № 3. – P. 47–51. – DOI: 10.24412/2071–5315-2020-12256.
4. Vasil’eva, L. N., Rubahova N. N., Nikitina E. V., Loba chevskaya O. S., Sokolovskaya D. O. Sovremennye podhody k diagnostike i lecheniyu klimaktericheskih narushenij // Medicinskij zhurnal. – 2018. – № 2. – S. 142–146.
5. Vasil’eva, L. N., Rubahova N. N., Nikitina E. V., Sokolovskaya D. O. Menopauzal’naya gormonoterapiya: za ili protiv? // Medicinskij zhurnal. – 2019. – № 3 (66). – S. 142–146.
6. Vasil’eva, L. N., Rubahova N. N., Nikitina E. V., Sokolovskaya D. O. Klimaktericheskij period: voprosy kontracepcii i menopauzal’noj gormonoterapii // Medicinskij zhurnal. – 2020. – № 2. – S. 126–130.
7. 52016 IMS Recommendations on women’s midlife health and menopause hormone therapy / R. J. Baber, N. Ranay & A. Fenton the IMS Writing Group. – M.: Taylor & Francis Group, 2016. – S. 110–150.
8. The 2017 hormone therapy position statement of the North American Menopause Society / Representatives of the NAMS of Trustes and other experts in women’s health. – M.: NAMS, 2017. – S. 728–753.
9. McGonagle, D., O’Donnell J. S., Sharif K., Emery P., Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia // Lancet Rheumatol. – 2020. – № 2 (7). – P. e437–e445. – DOI: 10.1016/S2665-9913(20)30121-1.
10. Lodigiani, C., Iapichino G., Carenzo L. et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy // Thromb Res. – 2020. – Vol. 191. – P. 9–14. – DOI: 10.1016/j.thromres.2020.04.024.
11. Escher, R., Breakey N., Lämmle B. Severe COVID-19 infection associated with endothelial activation // Thromb Res. – 2020. – Vol. 190. – P. 62. – DOI: 10.1016/j.thromres.2020.04.014.
12. Alvarado-Moreno, J. A., Majluf-Cruz A. COVID-19 and Dysfunctional Endothelium: The Mexican Scenario // Arch Med Res. – 2020. – Vol. 51 (6). – P. 587–8. – DOI: 10.1016/j.arcmed.2020.05.004.
13. Cagnacci, A., Bonaccorsi G., Gambacciani M. Board of the Italian Menopause Society. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued? // Maturitas. – 2020. – Vol. 138. – P. 76–7. – DOI: 10.1016/j.maturitas.2020.05.022.
14. Iba, T., Connors, J. M. & Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19 // Inflamm. Res. – 2020. – Vol. 69. – P. 1181–1189.
15. Windyga, J. COVID 19 a zaburzenia hemostazy // Med. Prakt. – 2020. – № 7–8. – P. 59–68.
Review
For citations:
Vasil'eva L.N., Nikitina E.V., Lobachevskaya O.S., Rubahova N.N. Hormonal therapy for climacteric syndrome under the new coronavirus infection COVID-19. Medical Journal. 2022;(4):144-149. (In Russ.) https://doi.org/10.51922/1818-426X.2022.4.144
Views:
11
Email this article 